Efficacy of Xeligekimab (GR1501) in Patients With Moderate to Severe Plaque Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The British Journal of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
Br J Dermatol 2024 Feb 15;[EPub Ahead of Print], L Cai, C Jiang, G Zhang, H Fang, J Wang, Y Li, H Xu, R Xiao, Y Ding, K Huang, C Zhang, L Zhang, B Chen, X Duan, W Pan, G Han, R Chen, L Liu, S Zhang, J Tao, X Pang, J Yu, H Wang, Y Zhao, C Li, X Kang, L Qin, X Zhu, J Su, S Li, C Yang, W Feng, T Lei, S Jiang, R Fang, M Lin, Q Lu, C Xu, W Wang, J ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.